Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments have also participatd in the round. Imara will develop IMR-687, a disease-modifying therapeutic selected specifically to treat sickle cell
Under the exclusive channel collaboration (ECC), AmpliPhi received an exclusive worldwide license to use Intrexon’s technology for the standardized production of wild type phages and for the design
The agency will review the submission under priority review status which reduces the review time to six months from the standard 10 months. In May 2014, the FDA
The funding was led by Longitude Capital with participation from OrbiMed, Vivo Capital, CAM Capital, RA Capital Management, Wellington Management, Polaris Partners, Lux Capital and CVF LLC. With
Rociletinib is indicated to treat patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been earlier treated with an EGFR-targeted therapy and
The agency granted Keytruda priority review status with a target action date of 9 August 2016. Keytruda was approved in 2014 to treat melanoma. In October 2015, it
ATI-1501 is the company’s lead drug candidate, which is expected to enter into clinical trials by 2017. The orphan drug status offers seven years of marketing exclusivity after
The company introduced a cloud version of Oracle Health Sciences Safety Suite 8.0, targeting medicinal product manufacturers, trial sponsors, contract research organizations and health authorities. The solution offers
APD371 is the company’s internally discovered investigational drug candidate aimed at treating pain and potentially other indications. The compound, via its selectivity, is designed to offer pain relief
TSC is a rare genetic condition characterized by formation of non-malignant tumors in several organs. The 16-week dose-ranging trial will evaluate Epidiolex against placebo in about 200 patients.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.